The application of tissue engineering technology to wound healing has resulted in the development of a number of “living skin equivalents.” These have become a viable option in the treatment of chronic, nonhealing wounds. Such wounds present a major cost burden as well as increased morbidity and mortality. Unique among skin tissue engineering technology is the TissueTech autograft system, as it incorporates an autologous dermal substitute—Hyalograft® 3D—and an autologous epidermal replacement, Laserskin® autograft. Each includes a matrix of a hyaluronic acid ester to promote cellular migration and graft take.
Get full access to this article
View all access options for this article.
References
1.
1. Harding KG, Morris HL, Patel GK. Science, medicine and the future: healing chronic wounds . BMJ2002;324: 160-163 .
2.
2. Shen JT, Falanga V. Growth factors, signal transduction, and cellular responses . J Dermatol2003;30(1): 5-16 .
3.
3. Pham HT, Rosenblum BI, Lyons TE, et al. Evaluation of a human skin equivalent for the treatment of diabetic foot ulcers in a prospective, randomised, clinical trial . Wounds1997;11(4): 79-86 .
4.
4. Pollak RA, Edington H, Jensen JL, et al. A human dermal replacement for the treatment of diabetic foot ulcers . Wounds1997;9(1): 175-183 .
5.
5. Brem H, Balledux J, Bloom T, et al. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing . Arch Surg2000;135: 627-634 .
6.
6. Sorensen JC. Living skin equivalents and their application in wound healing . Clin Podiatr Med Surg1998;15(1): 129-137 .
7.
7. Boyce ST, Warden GD. Principles and practice for treatment of cutaneous wounds with cultured skin substitutes . Am J of Chronic Surg2002;183(4): 445-456 .
8.
8. Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent . Human Skin Equivalent Investigators Group. Arch Dermatol1998;134: 293-300 .
9.
9. Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers . Diabetes Care1996;19: 350-354 .
10.
10. Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent is effective in the management of non-infected neuropathic diabetic foot ulcers . Diabetes Care2001;24: 290-295 .
11.
11. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human replacement for the treatment of diabetic foot ulcers . Artif Organs1997;21(11): 1203-1210 .
12.
12. Kirsner RS, Falanga V, Kerdel FA, et al. Skin grafts as pharmacological agents: pre-wounding of the donor site . Br J Dermatol1996;135(2): 292-296 .
13.
13. Chen WYJ, Abatangelo G. Functions of hyaluronan in wound repair . Wound Rep Regen1999;7: 79-89 .
14.
14. Campoccia D, Doherty P, Radice M, et al. Semi-synthetic resorbable materials from hyaluronan derivatization . Biomaterials1998;19: 2101-2127 .
15.
15. Caravaggi C, De Giglio R, Pritelli C, et al. HYAFF® 11-based autologous dermal and epidermal grafts in the treatment of non-infected, diabetic plantar and dorsal foot ulcers: a prospective, multicentre controlled, randomised clinical trial [In press]. Diabetes Care.
16.
16. AndreassiL, CassiniL, Trabucchi E, et al. Human keratinocytes cultured on membranes composed of benzyl ester of hyaluronic acid suitable for grafting . Wounds1991;3: 116-126 .
17.
17. Scalise A, Pierangeli M, Di Benedetto G, et al. Cultured autologous fibroblast and keratinocyte grafts: applications in plastic surgery . Ann Burns Fire Disasters2001;14(2): 96-99 .
18.
18. Hollander DA, Soranzo C, Falk S, et al. Extensive traumatic soft tissue loss; reconstruction in severely injured patients using cultured hyaluronan-based three-dimensional dermal and epidermal autografts . J Trauma2001;50(6): 1125-1136 .
19.
19. Faglia E, Mantero M, Gino M, et al. A combined conservative approach in the treatment of a severe Achilles tendon region ulcer in a diabetic patient: a case report . Wounds1999;11(5): 105-109 .
20.
20. Dalla Paola L, Cogo A, Deanesi W, et al. Using hyaluronic acid derivatives and cultured autologous fibroblasts and keratinocytes in a lower limb wound in a patient with diabetes; a case report . Ostomy Wound Manage2002;48(9): 46-49 .
21.
21. Harris PA, di Francesco F, Barisoni D, et al. Use of hyaluronic acid and cultured autologous keratinocytes and fibroblasts in extensive burns . Lancet1999;353: 35-36 .
22.
22. Oyibo SO, Jude EB, Tarawneh I, et al. The effects of ulcer size and site, patient's age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers . Diabet Med2001;18: 133-138 .
23.
23. Treiman GS, Copland S, McNamara RM, et al. Factors influencing ulcer healing in patients with combined arterial and venous insufficiency . J Vasc Surg2001;33(6): 1158-1164 .
24.
24. Margolis D, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment: a meta-analysis . Diabetes Care1999;22(5): 692-695 .
25.
25. Pham HT, Rich J, Veves A. Using living skin equivalents for diabetic foot ulceration . Lower Extrem Wounds2002;1(1): 27-32 .
26.
26. Lyon RT, Veith FJ, Bolton L, et al. Clinical benchmark for healing venous ulcers . Am J Surg1998;176(2): 172-175 .
27.
27. Meaume S, Gemmen E. Cost-effectiveness of wound management in France: pressure ulcers and venous leg ulcers . J Wound Care2002;11(6): 219-224 .
28.
28. Skene AI, Smith JM, Dorè CJ, Charlett A, et al. Venous leg ulcers: a prognostic index to predict time to healing . BMJ1993;305: 1119-1121 .
29.
29. Phillips T, Kehinde O, Green H, et al. Treatment of skin ulcers with Cultured epidermal allografts . J Am Acad Dermatol1989; 21: 191-199 .
30.
30. Apelqvist J, Larsson J. What is the most effective way to reduce the incidence of amputation in the diabetic foot? Diab Metab Res Rev2000;16(Suppl 1): S75-S83 .
31.
31. Dalla Paola LD, Faglia E, Caminiti M, et al. Ulcer recurrence in diabetic patients: a cohort prospective study . Diabetes Care2003;26(6): 1874-1878 .
